Date published: 2025-11-21

1-800-457-3801

SCBT Portrait Logo
Seach Input

Herc2 Inhibitors

Herc2 Inhibitors represent a distinct chemical class targeting the HECT domain-containing E3 ubiquitin ligase, Herc2. This protein plays a pivotal role in the ubiquitination process, which is fundamental in regulating protein degradation, DNA repair mechanisms, and signal transduction pathways. Herc2 inhibitors typically function by impeding the protein's ubiquitin ligase activity. This inhibition is achieved through various mechanisms, such as binding to the active sites of the enzyme, interfering with its substrate recognition capabilities, or hindering the enzyme's ATPase activity. These inhibitors are chemically diverse, encompassing small molecules that exhibit specificity and high affinity for Herc2. The molecular structures of these inhibitors are often characterized by functional groups capable of forming strong interactions with the enzyme, such as hydrogen bonds, hydrophobic interactions, and Van der Waals forces. These interactions are crucial for the stability and efficacy of the inhibition.

The development of Herc2 inhibitors is guided by a deep understanding of the enzyme's structure and function. Herc2 contains several domains, including a HECT domain responsible for its ubiquitin ligase activity. Inhibitors are designed to target this domain specifically, aiming to disrupt the transfer of ubiquitin from the E2 enzyme to the substrate proteins. Some inhibitors may also target the regulatory regions of Herc2, thus modifying its conformation and reducing its enzymatic activity. The specificity of these inhibitors is of paramount importance to minimize off-target effects. Furthermore, the pharmacokinetic properties of these inhibitors, such as solubility, stability, and bioavailability, are key factors in their design. Herc2 inhibitors, by modulating the ubiquitination process, have the potential to influence various cellular pathways controlled by protein degradation, thereby contributing to the understanding of these pathways at a molecular level. The study of Herc2 inhibitors is primarily focused on elucidating the intricate mechanisms of protein regulation and the role of ubiquitination in cellular processes.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

MG-132 [Z-Leu- Leu-Leu-CHO]

133407-82-6sc-201270
sc-201270A
sc-201270B
5 mg
25 mg
100 mg
$56.00
$260.00
$980.00
163
(3)

A potent, reversible, and cell-permeable proteasome inhibitor, indirectly affecting the ubiquitination process by preventing the degradation of ubiquitinated proteins.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

A proteasome inhibitor that blocks the degradation of ubiquitin-protein conjugates, indirectly influencing the Herc2-related ubiquitination pathway.

Ubiquitin E1 Inhibitor, PYR-41

418805-02-4sc-358737
25 mg
$360.00
4
(1)

A selective, irreversible inhibitor of the ubiquitin-activating enzyme E1, indirectly affecting the Herc2-mediated ubiquitination by disrupting the upstream ubiquitination cascade.

MLN 4924

905579-51-3sc-484814
1 mg
$280.00
1
(0)

An inhibitor of NEDD8-activating enzyme, affecting the neddylation pathway, which is closely related to ubiquitination and may indirectly influence Herc2 activity.

Lactacystin

133343-34-7sc-3575
sc-3575A
200 µg
1 mg
$165.00
$575.00
60
(2)

An irreversible proteasome inhibitor, affecting the ubiquitin-proteasome pathway and thereby potentially influencing Herc2 activity.

Carfilzomib

868540-17-4sc-396755
5 mg
$40.00
(0)

A selective proteasome inhibitor, used to block the degradation of ubiquitinated proteins, indirectly impacting Herc2's function.

Epoxomicin

134381-21-8sc-201298C
sc-201298
sc-201298A
sc-201298B
50 µg
100 µg
250 µg
500 µg
$134.00
$215.00
$440.00
$496.00
19
(2)

A selective and potent proteasome inhibitor, impacting the ubiquitin-proteasome system and indirectly affecting Herc2 activity.

PR 619

2645-32-1sc-476324
sc-476324A
sc-476324B
1 mg
5 mg
25 mg
$75.00
$184.00
$423.00
1
(0)

A broad-spectrum deubiquitinase inhibitor, potentially impacting Herc2 function by altering the ubiquitination/deubiquitination balance.

Oprozomib

935888-69-0sc-477447
2.5 mg
$280.00
(0)

An bioavailable proteasome inhibitor, affecting the degradation of ubiquitinated proteins and thereby indirectly impacting Herc2.